ResearchMoz added Latest Research Report titled " Global Antibody Conjugates Drugs Market 2016-2020 " to it's Large Report database.
About Antibody Drug Conjugates
ADCs, empowered monoclonal antibodies (mAbs), use chemical linkers with labile bonds to attach biologically active substances. ADCs target mAbs with the cancer killing ability of cytotoxic drugs, allowing sensitive discernment between healthy and diseased tissue.
Antibodies are the proteins produced by B-cells (from bone marrow) in the immune system. These proteins attach to antigens, which act as markers, and are then destroyed by phagocytes. B-cells produce different antibodies that attach to different sites of an antigen. mAbs, complex proteins with high molecular weight, are monospecific as they are the clones of a single parent cell. They are of three types, chimeric, humanized, and fully human, and are often used for therapeutic and diagnostic purposes.
Technavios analysts forecast the global ADCs market to grow at a CAGR of 41.58% during the period 2016-2020.
Request for Sample PDF of Premium Research Report with TOC: http://www.researchmoz.us/enquiry.php?type=S&repid=700592
Covered in this report
The report covers the present scenario and the growth prospects of the global ADCs market for the period 2015-2020. To calculate the market size, the report considers revenue generated from the sales of ADCs used to treat cancer.
The market is divided into the following segments based on geography:
Americas
APAC
EMEA
Technavio's report, Global Antibody Drug Conjugates Market 2016-2020, has been prepared based on an in-depth market analysis with inputs from industry experts. The report covers the market landscape and its growth prospects over the coming years. The report also includes a discussion of the key vendors operating in this market.
Browse more details @ http://www.researchmoz.us/global-antibody-conjugates-drugs-market-2016-2020-report.html
Table of Content
PART 01: Executive summary
Highlights
PART 02: Scope of the report
Market overview
Top-vendor offerings
Assumptions
PART 03: Market research methodology
Research methodology
Economic indicators
PART 04: Introduction
Key market highlights
PART 05: Overview of ADCs
Antibodies
Evolution of mAb therapeutics
Conjugated mAbs
History
Key components in ADCs
Next-generation ADCs
Advantages
Challenges
Outsourcing of ADCs manufacturing
Emergence of ADCs
Current marketed ADCs
PART 06: Pipeline portfolio
Information on pipeline candidates
About ResearchMoz
ResearchMoz is the world's fastest growing collection of market research reports worldwide. Our database is composed of current market studies from over 100 featured publishers worldwide. Our market research databases integrate statistics with analysis from global, regional, country and company perspectives. ResearchMoz's service portfolio also includes value-added services such as market research customization, competitive landscaping, and in-depth surveys, delivered by a team of experienced Research Coordinators.
Contact Us:
Mr. Nachiket Ghumare
90 State Street, Albany NY, United States - 12207
Tel: +1-518-621-2074 / Tel: 866-997-4948 (Us-Canada Toll Free)
Email: sales@researchmoz.us
Follow us on LinkedIn at: http://bit.ly/1TBmnVG
Follow me on Blogger at: http://healthcare-research-report.blogspot.in/
About Antibody Drug Conjugates
ADCs, empowered monoclonal antibodies (mAbs), use chemical linkers with labile bonds to attach biologically active substances. ADCs target mAbs with the cancer killing ability of cytotoxic drugs, allowing sensitive discernment between healthy and diseased tissue.
Antibodies are the proteins produced by B-cells (from bone marrow) in the immune system. These proteins attach to antigens, which act as markers, and are then destroyed by phagocytes. B-cells produce different antibodies that attach to different sites of an antigen. mAbs, complex proteins with high molecular weight, are monospecific as they are the clones of a single parent cell. They are of three types, chimeric, humanized, and fully human, and are often used for therapeutic and diagnostic purposes.
Technavios analysts forecast the global ADCs market to grow at a CAGR of 41.58% during the period 2016-2020.
Request for Sample PDF of Premium Research Report with TOC: http://www.researchmoz.us/enquiry.php?type=S&repid=700592
Covered in this report
The report covers the present scenario and the growth prospects of the global ADCs market for the period 2015-2020. To calculate the market size, the report considers revenue generated from the sales of ADCs used to treat cancer.
The market is divided into the following segments based on geography:
Americas
APAC
EMEA
Technavio's report, Global Antibody Drug Conjugates Market 2016-2020, has been prepared based on an in-depth market analysis with inputs from industry experts. The report covers the market landscape and its growth prospects over the coming years. The report also includes a discussion of the key vendors operating in this market.
Browse more details @ http://www.researchmoz.us/global-antibody-conjugates-drugs-market-2016-2020-report.html
Table of Content
PART 01: Executive summary
Highlights
PART 02: Scope of the report
Market overview
Top-vendor offerings
Assumptions
PART 03: Market research methodology
Research methodology
Economic indicators
PART 04: Introduction
Key market highlights
PART 05: Overview of ADCs
Antibodies
Evolution of mAb therapeutics
Conjugated mAbs
History
Key components in ADCs
Next-generation ADCs
Advantages
Challenges
Outsourcing of ADCs manufacturing
Emergence of ADCs
Current marketed ADCs
PART 06: Pipeline portfolio
Information on pipeline candidates
About ResearchMoz
ResearchMoz is the world's fastest growing collection of market research reports worldwide. Our database is composed of current market studies from over 100 featured publishers worldwide. Our market research databases integrate statistics with analysis from global, regional, country and company perspectives. ResearchMoz's service portfolio also includes value-added services such as market research customization, competitive landscaping, and in-depth surveys, delivered by a team of experienced Research Coordinators.
Contact Us:
Mr. Nachiket Ghumare
90 State Street, Albany NY, United States - 12207
Tel: +1-518-621-2074 / Tel: 866-997-4948 (Us-Canada Toll Free)
Email: sales@researchmoz.us
Follow us on LinkedIn at: http://bit.ly/1TBmnVG
Follow me on Blogger at: http://healthcare-research-report.blogspot.in/
No comments:
Post a Comment